Advances in Anatomic Pathology:
Castleman Disease: An Update on Classification and the Spectrum of Associated Lesions
Cronin, Danielle M. P. MD; Warnke, Roger A. MD
Department of Pathology, Stanford University School of Medicine, Stanford, CA
Reprints: Danielle M. P. Cronin, MD, Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, Lane 235, Stanford, CA 94304 (e-mail: email@example.com).
The authors report no financial or other conflicts of interest.
Since its initial description, researchers have expanded the spectrum of Castleman disease to include not only the classic and well-recognized hyaline-vascular type, but also the plasma cell type and multicentric types of broader histologic range, including human herpes virus-8-associated Castleman disease. These less common subtypes of Castleman disease are less familiar, and may be under-recognized. Also of practical importance, current authors are restructuring the classification of multicentric Castleman disease to accommodate the emerging pathogenic role of human herpes virus-8 and its association with the recently described plasmablastic variant. In addition to an increased risk of lymphoma, patients with Castleman disease also are at increased risk for other related neoplasms, including Kaposi sarcoma and follicular dendritic cell tumors, which are of prognostic and therapeutic relevance. This review focuses on the histologic diagnosis of Castleman disease, current and emerging concepts in its pathogenesis and classification, and associated histopathologic entities.
Among the more common causes of non-neoplastic lymphadenopathy, it is important to recognize and accurately diagnose Castleman disease (CD, also known as angiofollicular lymph node hyperplasia and giant lymph node hyperplasia). Although the classic hyaline-vascular type may be well-recognized, it is the less distinctive human herpes virus-8 (HHV-8)-associated type of CD that has been the subject of recent research and significant advances. In recent years, it has become clear that CD is a morphologic syndrome uniting a group of diseases with related and occasionally overlapping pathogenesis. Recent authors favor classifying CD by histopathogenic type as opposed to the traditional unicentric versus multicentric model1,2 and we will follow that model in this review (Table 1). Clinical diagnosis and treatment of CD are not covered and have been addressed in 2 relatively recent reviews.3,4
CD was so-termed in reference to a series of 13 cases of localized mediastinal lymph-node hyperplasia described by Dr Benjamin Castleman in 1956.5 A variant rich in plasma cells was described by Flendrig and Schillings in 19696 and further defined in 1972, when Keller et al,7 distinguished the classically described “hyaline-vascular type” from the “plasma cell type,” which was less common and associated with systemic signs and/or symptoms. Although these early papers described localized processes, several authors subsequently noted multicentric lymphadenopathies associated with the constitutional symptoms and histologic features similar to the unicentric types of CD.8–11 A decade later came the discovery of a novel human herpes virus associated with Kaposi sarcoma (Kaposi sarcoma-associated herpes virus or HHV-8).12,13 HHV-8 was subsequently identified in primary effusion (or body-cavity-based) lymphomas14 and in multicentric CD, particularly in human immunodeficiency virus (HIV)-positive individuals.15,16 Since that discovery, there have been remarkable advances in our understanding of the pathogenesis of HHV-8-related CD.
HYALINE-VASCULAR CASTLEMAN DISEASE
The histologically classic hyaline-vascular form usually presents unicentrically, involving a single node or localized group of nodes (76% to 91% of localized CD).7,17,18 It presents in roughly equal numbers of young adult men and women. The median age of presentation is in the fourth decade,5,7,17–19 although the age range is broad and pediatric cases have been reported.20,21 This form of CD presents as a localized mass, most frequently occurring in a thoracic lymph node,5,7,17,18,22 although various extranodal presentations also occur.18,23–25 Most cases of localized hyaline-vascular CD present with a mass lesion and lack the systemic signs and/or symptoms associated with the plasma cell and multicentric forms of CD.7,18 The pathogenesis is unknown, but a relationship to dysplastic follicular dendritic cells has been suggested.1 Vascular endothelial growth factor may contribute to the prominent vascular proliferation seen in this subtype of CD.2
Histologically, hyaline-vascular CD is characterized by distinctive follicles with expanded mantle zones of small lymphocytes forming concentric rings surrounding 1 or more atretic germinal centers. There is prominent vascularity of the germinal centers, often with a single prominent penetrating vessel. Another important feature is vascular proliferation between the follicles, often with perivascular hyalinization.
The “onion-skinning” of mantle zone lymphocytes, together with the prominent central vessel, has been likened to the appearance of a lollipop (Fig. 1).26
Association—Dendritic Cell and Vascular Proliferations
Lymph nodes involved by hyaline-vascular CD are known to have alterations in the follicular dendritic cell networks,26–28 with reports of proliferations of dysplastic follicular dendritic cells (Fig. 2) and follicular dendritic cell tumors (Fig. 3).29,30 Some studies have demonstrated clonal cytogenetic abnormalities in these proliferations.31,32 Pathologists should be aware of these follicular dendritic cell proliferations, as their exact relationship with dendritic cell sarcomas is unknown. The association between hyaline-vascular CD and dendritic cell sarcomas is well documented, with some cases behaving in a malignant fashion.29,30,33–38 Although it is not thought to play a role in the pathogenesis of hyaline-vascular CD, 1 study showed that HHV-8 is not typically found in follicular dendritic cell sarcoma associated with CD.39
In addition to dendritic cell tumors, small case series and anecdotal descriptions also mention various vascular tumors40 and abnormal collections of plasmacytoid dendritic cells (previously referred to as “plasmacytoid T-cells and plasmacytoid monocytes”) (Fig. 4).22,41,42 The significance of these associations is uncertain due to the relative infrequency of their reports in the literature.
PLASMA-CELL CASTLEMAN DISEASE
The plasma cell type of CD is more commonly multicentric than unicentric, and represents 9% to 24% of localized CD.7,17,18 The localized form occurs in a similar patient population as the hyaline-vascular type18; however, the unicentric plasma cell variant is more likely to be associated with the systemic symptoms and abnormal laboratory findings.6,7,18 The most often described clinical findings include fevers, night sweats, malaise, splenomegaly, hypergammaglobulinemias, and cytopenias such as anemia and thrombocytopenia.7,17,18 The localized form of plasma cell CD is probably the least well characterized, with many cases likely representing multicentric plasma cell CD.26 In support of this argument, cases of unicentric plasma cell CD seem to be associated with the increase in serum interleukin (IL)-6, similar to multicentric CD; however, surgical excision is reportedly curative in localized plasma cell CD, as opposed to multicentric CD, which requires systemic therapy.43–48 Both the unicentric and multicentric forms of plasma cell CD have also been associated with POEMS syndrome, a clinical syndrome involving polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes.49–52
In contrast to hyaline-vascular type, plasma cell CD has less distinctive histologic features. There is retained lymph node architecture, with variable germinal center hyperplasia with expanded mantle zones and a marked paracortical plasmacytosis. When localized, this type usually affects an aggregate mass of lymph nodes, as opposed to a dominant lymph node in hyaline-vascular unicentric CD.7 There is usually a population of larger plasmablasts (plasmacytoid immunoblasts) that localize to the mantle zone or paracortical regions. As these histologic features are nonspecific, exclusion of other entities that may simulate plasma cell CD is of paramount importance. HHV-8-associated CD must be excluded with clinical information and immunohistochemical staining. Other entities in the differential diagnosis include B-cell lymphomas (such as marginal zone B-cell lymphomas with prominent reactive follicles and plasmacytic differentiation), rare plasmacytomas, and reactive lymphadenopathies associated with infection, autoimmune diseases such as rheumatoid arthritis or reactive lymphoadenopathies associated with other immunodeficiencies.2,26,53 In addition, various HIV-related lymphadenopathies may be difficult to distinguish from multicentric CD.54 The presence of hyaline-vascular type follicles in some cases with a plasma cell component provides a link to the hyaline-vascular type, and some have designated such examples as mixed or transitional types.26 Plasma cells may be monotypic and usually express λ-restricted light chains (either IgG or IgA) (Fig. 5), especially in cases associated with osteosclerotic myeloma or POEMS syndrome.52,55–58
Pathogenesis—the Role of Interleukin-6
The association between the systemic features of plasma cell CD and a factor secreted by affected lymph nodes was recognized in 1989.48 Subsequently known as IL-6, this B-stimulatory cytokine was intimately linked with the systemic manifestations of CD.43,45,47,59 IL-6 was shown to induce a CD-like condition in mice44 and induce B-cell proliferation in other B-cell malignancies.60 In addition, therapy with anti-IL-6 antibodies resulted in complete (although in some cases temporary) resolution of the systemic manifestations of CD in patients.46,61 Interestingly, the genome of HHV-8 encodes a viral analog to human IL-6.62,63 Viral IL-6 is known to have both hematopoietic and angiogenic effects,64–66 although the exact role of viral IL-6 in the pathogenesis of HHV-8-related diseases has yet to be elucidated.4
MULTICENTRIC CASTLEMAN DISEASE, NOT OTHERWISE SPECIFIED
Although older literature considered all cases of multicentric CD together, it is now known that a significant subset of cases are associated with HHV-8 infection. The form of multicentric CD associated with HHV-8 infection occurs frequently in the HIV-positive patient population and is discussed separately below. As these cases were not distinguished in many of the older case series, it is difficult to interpret historical literature concerning multicentric CD. Regardless, there are cases of multicentric CD unrelated to HHV-8 infection, usually of the plasma cell or intermediate types, which fall into the waste-basket of “multicentric CD, not otherwise specified.”2 It is especially important to note that this is a diagnosis of exclusion. In general, multicentric CD presents with generalized or multicentric lymphadenopathy with histologic features of CD (usually the plasma cell type) and often with relatively preserved lymph node architecture. The patient population is generally older than that of localized CD, with the median age being in the sixth decade. The systemic features are similar to those occurring in the unicentric plasma cell type of CD described previously.8,11,17,18,53,67
HUMAN HERPES VIRUS-8-ASSOCIATED (PLASMABLASTIC) MULTICENTRIC CASTLEMAN DISEASE
Although the unique natural history of multicentric CD is still being elucidated, it is known that this entity occurs most frequently in immunosuppressed individuals, especially the HIV-positive patient population. This CD variant is referred to variably as the HHV-8-positive, HHV-8-associated, or plasmablastic variant of CD.2,68–71 It is unknown exactly what percentage of multicentric CD is caused by HHV-8, but most studies looking for viral particles in cases of multicentric CD have shown high rates of HHV-8 infection, especially in HIV-positive patients.15,72–82 In fact, to the best of our knowledge, only a single case of multicentric CD associated with HIV-infection tested negative for HHV-8.83 It is now thought that HHV-8-associated multicentric CD represents a distinct entity with a risk of progression to a particular form of large B-cell lymphoma (HHV-8-positive plasmablastic lymphoma). The prognosis of HHV-8-associated multicentric CD in general is poor, with the survival being generally on the order of months.26,84
Histopathology and “Microlymphomas”
Initial studies showed that in a subset of cases previously called multicentric plasma cell CD, the plasmablastic cells (plasmacytoid immunoblasts) express an HHV-8-related antigen (specifically, latency-associated nuclear antigen-1) by immunohistochemistry.63,68,85 Subsequently, these particular HHV-8-positive plasmablasts were found to uniformly express cytoplasmic IgM and λ-restricted light chains.68,71 Histologically similar to plasma cell CD, HHV-8-positive CD may have distinct features, in addition to expressing HHV-8 related antigens by immunohistochemistry. In most cases of HHV-8-positive CD, these “plasmablasts” are scattered throughout the interfollicular regions among the plasma cell infiltrate; however, expansions of these plasmablasts may form microscopic collections (microlymphomas) (Fig. 6) and form frank HHV-8-associated plasmablastic lymphomas in others. Initially the IgM λ-restricted plasmablasts are monotypic, but polyclonal, and may progress to monoclonal proliferations later in the disease course. 68,86
Association—Large B-cell Lymphoma Arising in Human Herpes Virus-8-associated Multicentric Castleman Disease (Human Herpes Virus-8-positive Plasmablastic Lymphoma)
The current World Health Organization classification of hematopoietic tumors now distinguishes large B-cell lymphomas arising in the setting of HHV-8-positive CD as a separate entity, called “large B-cell lymphoma arising in HHV-8-associated multicentric CD” or HHV-8-positive plasmablastic lymphoma.58 The entity was distinguished from classic plasmablastic lymphomas arising in other settings because the neoplastic cells show a genetically distinct neoplastic population, having arisen from naive, IgM-producing plasma cells without immunoglobulin hypermutation. In addition to HHV-8-positive plasmablastic lymphoma, multicentric CD seems to be associated with an increased risk of other types of lymphoma, which is further discussed below.
Clonality in Human Herpes Virus-8-positive Multicentric Castleman Disease
Early investigators sought to understand the nature of multicentric CD, and interestingly mention λ-restricted proteinopathies or plasma cell populations throughout the history of CD.55,57,71,87–89 Despite identification of these monotypic λ-restricted populations in HHV-8-positive CD, rigorous studies have shown that these cases are not necessarily monoclonal, with many lacking clonal immunoglobulin gene rearrangements by molecular techniques.31,55–57,68,69,88,90–94 More recent authors have speculated that IgM λ-monotypic B-cells may represent a distinct population of IgM-positive naive B-cells that are infected by HHV-8, which expand to form neoplastic proliferations later in the disease course. This hypothesis has been tentatively and theoretically compared with the better-understood process of lymphoproliferation associated with Epstein-Barr virus (EBV)-infections.69
Association—“Kaposi Sarcoma-associated Herpes Virus-associated Germinotropic Lymphoproliferative Disorder”
Several authors have noted coinfection with HHV-8 and EBV in CD, although no clear significance of this association was ever demonstrated.21,95–97 In 2002, Du et al86 described a form of localized lymphadenopathy with morphologic features similar to those seen in HHV-8-associated multicentric CD, but with coinfection of the plasmablastic population by both HHV-8 and EBV. The plasmablastic population in these cases showed polyclonal or oligoclonal patterns of immunoglobulin gene rearrangement, with 1 case demonstrating switched IgA heavy chains. The patients in this small series had favorable response to chemotherapy or radiotherapy. As very few cases have been described, it is difficult to draw conclusions regarding this newly defined entity.
Association—Hodgkin and Other Forms of non-Hodgkin Lymphoma
In addition to the recently described progression of HHV-8-associated multicentric CD to large B-cell lymphoma (HHV-8-positive plasmablastic lymphoma), there is also an increased risk of other lymphoma types among both HIV-positive and HIV-negative subgroups.11,54,98–101 In fact, a recent cohort study demonstrated that there was a 15-fold increased risk of lymphoma among HIV-positive patients with multicentric CD over case-matched HIV-positive patients without CD.70 Hodgkin disease has also been rarely associated with CD, although the exact relationship between these entities is unclear.95,102–108 Despite the association with Hodgkin disease, one should be careful not to interpret dysplastic follicular dendritic cells as Reed-Sternberg cells.
Several case reports and small case series noted the coincidence of multicentric CD and vascular lesions including Kaposi sarcoma, even before the discovery of HHV-8.29,40,54,101,109–113 Now it is known that both diseases are associated with the same viral agent (HHV-8), and frequently occur together in the HIV-acquired immunodeficiency syndrome population.70 Although demonstrating distinct patterns of HHV-8 immunohistochemical staining with latency-associated nuclear antigen-1, multicentric CD and Kaposi sarcoma may be more that coincidentally linked.114,115 Viral IL-6 is known to have angiogenic activity,64,66 and vascular endothelial growth factor is thought to be a part of the pathophysiology of CD.116,117 A recent study showed that small foci of Kaposi sarcoma-like lesions were more frequently found in lymph nodes involved by multicentric CD than case-matched controls,115 and careful examination may reveal coexistence of the 2 entities (Fig. 7). Although the clinical significance of these microscopic HHV-8-positive vascular lesions is unknown, pathologists should be mindful of this association and its potential prognostic or therapeutic implications.
The spectrum of CD is broad, and seems to represent several related clinicopathologic entities. The emergence of HHV-8-related CD and the characterization of the plasmablastic variant have contributed to our understanding of this complex disorder, and generally to the pathogenesis of viral-related lymphoproliferative disorders. Despite our imperfect understanding of the complex pathogenesis of this disorder, pathologists must be aware of the various forms of CD and their relationship to follicular dendritic cell tumors, malignant lymphomas, and Kaposi sarcoma.
1. Hsi ED. Castleman Disease. Hematopathology. Philadelphia: Churchill Livingstone Elsevier; 2007:150–155.
2. McClain KL, Natkunam Y, Swerdlow SH. Atypical cellular disorders. Hematology (Am Soc Hematol Educ Program). 2004;1:283–296.
3. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol. 2005;129:3–17.
4. Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol. 2004;43:698–704.
5. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9:822–830.
6. Flendrig JA, Schillings PHM. Benign giant lymphoma: the clinical signs and symptoms. Folia Med Neerl. 1969;12:119–120.
7. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29:670–683.
8. Frizzera G, Banks PM, Massarelli G, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol. 1983;7:211–231.
9. Gaba AR, Stein RS, Sweet DL, et al. Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 1978;69:86–90.
10. Frizzera G, Peterson BA, Bayrd ED, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985;3:1202–1216.
11. Weisenburger DD, Nathwani BN, Winberg CD, et al. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol. 1985;16:162–172.
12. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266:1865–1869.
13. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med. 1995;332:1181–1185.
14. Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186–1191.
15. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86:1276–1280.
16. Dupin N, Gorin I, Deleuze J, et al. Herpes-like DNA sequences, AIDS-related tumors, and Castleman's disease. N Engl J Med. 1995;333:798; author reply 798–799.
17. Menke DM, Camoriano JK, Banks PM. Angiofollicular lymph node hyperplasia: a comparison of unicentric, multicentric, hyaline vascular, and plasma cell types of disease by morphometric and clinical analysis. Mod Pathol. 1992;5:525–530.
18. Frizzera G. Castleman's disease and related disorders. Semin Diagn Pathol. 1988;5:346–364.
19. Martin JM, Bell B, Ruether BA. Giant lymph node hyperplasia (Castleman's disease) of hyaline vascular type. Clinical heterogeneity with immunohistologic uniformity. Am J Clin Pathol. 1985;84:439–446.
20. Hunt SJ, Anderson WD. Giant lymph node hyperplasia of the hyaline vascular type with plasmacytoid T-cells and presentation in infancy. Am J Clin Pathol. 1989;91:344–347.
21. Smir BN, Greiner TC, Weisenburger DD. Multicentric angiofollicular lymph node hyperplasia in children: a clinicopathologic study of eight patients. Mod Pathol. 1996;9:1135–1142.
22. Danon AD, Krishnan J, Frizzera G. Morpho-immunophenotypic diversity of Castleman's disease, hyaline-vascular type: with emphasis on a stroma-rich variant and a new pathogenetic hypothesis. Virchows Arch A Pathol Anat Histopathol. 1993;423:369–382.
23. Kubota Y, Noto S, Takakuwa T, et al. Skin involvement in giant lymph node hyperplasia (Castleman's disease). J Am Acad Dermatol. 1993;29:778–780.
24. Sleater J, Mullins D. Subcutaneous Castleman's disease of the wrist. Am J Dermatopathol. 1995;17:174–178.
25. Kazakov DV, Fanburg-Smith JC, Suster S, et al. Castleman disease of the subcutis and underlying skeletal muscle: report of 6 cases. Am J Surg Pathol. 2004;28:569–577.
26. Weiss LM. Castleman Disease. Lymph Nodes. New York, NY: Cambridge University Press; 2008:25–32.
27. Nguyen DT, Diamond LW, Hansmann ML, et al. Castleman's disease. Differences in follicular dendritic network in the hyaline vascular and plasma cell variants. Histopathology. 1994;24:437–443.
28. Menke DM, Tiemann M, Camoriano JK, et al. Diagnosis of Castleman's disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies. Am J Clin Pathol. 1996;105:268–276.
29. Chan JK, Tsang WY, Ng CS. Follicular dendritic cell tumor and vascular neoplasm complicating hyaline-vascular Castleman's disease. Am J Surg Pathol. 1994;18:517–525.
30. Lin O, Frizzera G. Angiomyoid and follicular dendritic cell proliferative lesions in Castleman's disease of hyaline-vascular type: a study of 10 cases. Am J Surg Pathol. 1997;21:1295–1306.
31. Cokelaere K, Debiec-Rychter M, De Wolf-Peeters C, et al. Hyaline vascular Castleman's disease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of mesenchymal tumorigenesis. Am J Surg Pathol. 2002;26:662–669.
32. Pauwels P, Dal Cin P, Vlasveld LT, et al. A chromosomal abnormality in hyaline vascular Castleman's disease: evidence for clonal proliferation of dysplastic stromal cells. Am J Surg Pathol. 2000;24:882–888.
33. Chan AC, Chan KW, Chan JK, et al. Development of follicular dendritic cell sarcoma in hyaline-vascular Castleman's disease of the nasopharynx: tracing its evolution by sequential biopsies. Histopathology. 2001;38:510–518.
34. Kazakov DV, Morrisson C, Plaza JA, et al. Sarcoma arising in hyaline-vascular castleman disease of skin and subcutis. Am J Dermatopathol. 2005;27:327–332.
35. Marzano AV, Vezzoli P, Mariotti F, et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma and Castleman disease. Br J Dermatol. 2005;153:214–215.
36. Fornelli A, Mureden A, Eusebi V. Follicular dendritic cell tumor and unusual vascular lesion in lymph node with Castleman's disease. Description of a case. Pathologica. 1998;90:146–151.
37. Saiz AD, Chan O, Strauchen JA. Follicular dendritic cell tumor in Castleman's disease: a report of two cases. Int J Surg Pathol. 1997;5:25–30.
38. Katano H, Kaneko K, Shimizu S, et al. Follicular dendritic cell sarcoma complicated by hyaline-vascular type Castleman's disease in a schizophrenic patient. Pathol Int. 1997;47:703–706.
39. Nayler SJ, Taylor L, Cooper K. HHV-8 is not associated with follicular dendritic cell tumours. Mol Pathol. 1998;51:168–170.
40. Gerald W, Kostianovsky M, Rosai J. Development of vascular neoplasia in Castleman's disease. Report of seven cases. Am J Surg Pathol. 1990;14:603–614.
41. Harris NL, Bhan AK. “Plasmacytoid T cells” in Castleman's disease. Immunohistologic phenotype. Am J Surg Pathol. 1987;11:109–113.
42. Facchetti F, de Wolf-Peeters C, Mason DY, et al. Plasmacytoid T cells. Immunohistochemical evidence for their monocyte/macrophage origin. Am J Pathol. 1988;133:15–21.
43. Leger-Ravet MB, Peuchmaur M, Devergne O, et al. Interleukin-6 gene expression in Castleman's disease. Blood. 1991;78:2923–2930.
44. Brandt SJ, Bodine DM, Dunbar CE, et al. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest. 1990;86:592–599.
45. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989;74:1360–1367.
46. Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330:602–605.
47. Hsu SM, Waldron JA, Xie SS, et al. Expression of interleukin-6 in Castleman's disease. Hum Pathol. 1993;24:833–839.
48. Yabuhara A, Yanagisawa M, Murata T, et al. Giant lymph node hyperplasia (Castleman's disease) with spontaneous production of high levels of B-cell differentiation factor activity. Cancer. 1989;63:260–265.
49. Bitter MA, Komaiko W, Franklin WA. Giant lymph node hyperplasia with osteoblastic bone lesions and the POEMS (Takatsuki's) syndrome. Cancer. 1985;56:188–194.
50. Mandler RN, Kerrigan DP, Smart J, et al. Castleman's disease in POEMS syndrome with elevated interleukin-6. Cancer. 1992;69:2697–2703.
51. Belec L, Mohamed AS, Authier FJ, et al. Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease. Blood. 1999;93:3643–3653.
52. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101:2496–2506.
53. McCarty MJ, Vukelja SJ, Banks PM, et al. Angiofollicular lymph node hyperplasia (Castleman's disease). Cancer Treat Rev. 1995;21:291–310.
54. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10:61–67.
55. Radaszkiewicz T, Hansmann ML, Lennert K. Monoclonality and polyclonality of plasma cells in Castleman's disease of the plasma cell variant. Histopathology. 1989;14:11–24.
56. Hanson CA, Frizzera G, Patton DF, et al. Clonal rearrangement for immunoglobulin and T-cell receptor genes in systemic Castleman's disease. Association with Epstein-Barr virus. Am J Pathol. 1988;131:84–91.
57. Hall PA, Donaghy M, Cotter FE, et al. An immunohistological and genotypic study of the plasma cell form of Castleman's disease. Histopathology. 1989;14:333–346; discussion 429–432.
58. Isaacson PG, Campo E, Harris NL. Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Lyon: IARC; 2008:258–259.
59. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood. 2000;96:2069–2073.
60. van Kooten C, Rensink I, Aarden L, et al. Effect of IL-4 and IL-6 on the proliferation and differentiation of B-chronic lymphocytic leukemia cells. Leukemia. 1993;7:618–624.
61. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61.
62. Neipel F, Albrecht JC, Ensser A, et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol. 1997;71:839–842.
63. Parravicini C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol. 1997;151:1517–1522.
64. Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 1999;93:4034–4043.
65. Brousset P, Cesarman E, Meggetto F, et al. Colocalization of the viral interleukin-6 with latent nuclear antigen-1 of human herpesvirus-8 in endothelial spindle cells of Kaposi's sarcoma and lymphoid cells of multicentric Castleman's disease. Hum Pathol. 2001;32:95–100.
66. Klouche M, Brockmeyer N, Knabbe C, et al. Human herpesvirus 8-derived viral IL-6 induces PTX3 expression in Kaposi's sarcoma cells. AIDS. 2002;16:F9–F18.
67. Frizzera G, Kaneko Y, Sakurai M. Angioimmunoblastic lymphadenopathy and related disorders: a retrospective look in search of definitions. Leukemia. 1989;3:1–5.
68. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95:1406–1412.
69. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97:2130–2136.
70. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99:2331–2336.
71. Amin HM, Medeiros LJ, Manning JT, et al. Dissolution of the lymphoid follicle is a feature of the HHV8+ variant of plasma cell Castleman's disease. Am J Surg Pathol. 2003;27:91–100.
72. Yamasaki S, Iino T, Nakamura M, et al. Detection of human herpesvirus-8 in peripheral blood mononuclear cells from adult Japanese patients with multicentric Castleman's disease. Br J Haematol. 2003;120:471–477.
73. Suda T, Katano H, Delsol G, et al. HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int. 2001;51:671–679.
74. Kikuta H, Itakura O, Taneichi K, et al. Tropism of human herpesvirus 8 for peripheral blood lymphocytes in patients with Castleman's disease. Br J Haematol. 1997;99:790–793.
75. Gessain A, Sudaka A, Briere J, et al. Kaposi sarcoma-associated herpes-like virus (human herpesvirus type 8) DNA sequences in multicentric Castleman's disease: is there any relevant association in non-human immunodeficiency virus-infected patients? Blood. 1996;87:414–416.
76. Luppi M, Barozzi P, Maiorana A, et al. Human herpesvirus-8 DNA sequences in human immunodeficiency virus-negative angioimmunoblastic lymphadenopathy and benign lymphadenopathy with giant germinal center hyperplasia and increased vascularity. Blood. 1996;87:3903–3909.
77. Chadburn A, Cesarman E, Nador RG, et al. Kaposi's sarcoma-associated herpesvirus sequences in benign lymphoid proliferations not associated with human immunodeficiency virus. Cancer. 1997;80:788–797.
78. Cesarman E, Knowles DM. Kaposi's sarcoma-associated herpesvirus: a lymphotropic human herpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Semin Diagn Pathol. 1997;14:54–66.
79. Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol. 2000;156:743–749.
80. Menke DM, Chadbum A, Cesarman E, et al. Analysis of the human herpesvirus 8 (HHV-8) genome and HHV-8 vIL-6 expression in archival cases of Castleman disease at low risk for HIV infection. Am J Clin Pathol. 2002;117:268–275.
81. Corbellino M, Poirel L, Aubin JT, et al. The role of human herpesvirus 8 and Epstein-Barr virus in the pathogenesis of giant lymph node hyperplasia (Castleman's disease). Clin Infect Dis. 1996;22:1120–1121.
82. Barozzi P, Luppi M, Masini L, et al. Lymphotropic herpes virus (EBV, HHV-6, HHV-8) DNA sequences in HIV negative Castleman's disease. Clin Mol Pathol. 1996;49:M232–M235.
83. Izuchukwu IS, Tourbaf K, Mahoney MC. An unusual presentation of Castleman's disease:a case report. BMC Infect Dis. 2003;3:20.
84. Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol. 1993;20:636–647.
85. Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A. 1999;96:4546–4551.
86. Du MQ, Diss TC, Liu H, et al. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood. 2002;100:3415–3418.
87. Schlosnagle DC, Chan WC, Hargreaves HK, et al. Plasmacytoma arising in giant lymph node hyperplasia. Am J Clin Pathol. 1982;78:541–544.
88. Ohyashiki JH, Ohyashiki K, Kawakubo K, et al. Molecular genetic, cytogenetic, and immunophenotypic analyses in Castleman's disease of the plasma cell type. Am J Clin Pathol. 1994;101:290–295.
89. Chilosi M, Menestrina F, Lestani M, et al. Hyaline-vascular type of Castleman's disease (angiofollicular lymph node hyperplasia) with monotypic plasma cells. An immunohistochemical study with monoclonal antibodies. Histol Histopathol. 1987;2:49–55.
90. Soulier J, Grollet L, Oksenhendler E, et al. Molecular analysis of clonality in Castleman's disease. Blood. 1995;86:1131–1138.
91. Judde JG, Lacoste V, Briere J, et al. Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. J Natl Cancer Inst. 2000;92:729–736.
92. Wang L, Bu D, Yang Y, et al. Castleman's tumours and production of autoantibody in paraneoplastic pemphigus. Lancet. 2004;363:525–531.
93. Al-Maghrabi J, Kamel-Reid S, Bailey D. Immunoglobulin and T-cell receptor gene rearrangement in Castleman's disease: molecular genetic analysis. Histopathology. 2006;48:233–238.
94. Menke DM, DeWald GW. Lack of cytogenetic abnormalities in Castleman's disease. South Med J. 2001;94:472–474.
95. Caussinus E, Meggetto F, Delsol G, et al. Simultaneous occurrence of Epstein-Barr virus associated Hodgkin's disease and HHV-8 related multicentric Castleman's disease: a fortuitous event? J Clin Pathol. 2001;54:790–791.
96. Hernandez JL, Gomez-Roman J, Ramos-Estebanez C, et al. Human herpesvirus 8 and Epstein-Barr virus coinfection in localized Castleman disease during pregnancy. Haematologica. 2005;90(suppl):ECR35.
97. Larroche C, Agbalika F, Poirel H, et al. Epstein-Barr virus and human herpesvirus 8 coinfection and concomitant extranodal nasal-type NK/T cell lymphoma and Castleman disease: case report. Clin Infect Dis. 2003;36:e107–e110.
98. Perlow LS, Taff ML, Orsini JM, et al. Kaposi's sarcoma in a young homosexual man. Association with angiofollicular lymphoid hyperplasia and a malignant lymphoproliferative disorder. Arch Pathol Lab Med. 1983;107:510–513.
99. Larroche C, Cacoub P, Soulier J, et al. Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol. 2002;69:119–126.
100. Loi S, Goldstein D, Clezy K, et al. Castleman's disease and HIV infection in Australia. HIV Med. 2004;5:157–162.
101. Lachant NA, Sun NC, Leong LA, et al. Multicentric angiofollicular lymph node hyperplasia (Castleman's disease) followed by Kaposi's sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol. 1985;83:27–33.
102. Maheswaran PR, Ramsay AD, Norton AJ, et al. Hodgkin's disease presenting with the histological features of Castleman's disease. Histopathology. 1991;18:249–253.
103. Abdel-Reheim FA, Koss W, Rappaport ES, et al. Coexistence of Hodgkin's disease and giant lymph node hyperplasia of the plasma-cell type (Castleman's disease). Arch Pathol Lab Med. 1996;120:91–96.
104. Frank DK, Charney D, Kashani A. Plasma cell variant of Castleman's disease occurring concurrently with Hodgkin's disease in the neck. Head Neck. 2001;23:166–169.
105. Molinie V, Perie G, Melo I, et al. Association of Castleman's disease and Hodgkin's disease. Eight cases and review of the literature. Ann Pathol. 1994;14:384–391.
106. Pettit C, Ferry JA, Harris NL. Simultaneous occurrence of Hodgkin's disease with coexistent Castleman-like histologic features. Arch Pathol Lab Med. 1991;64:81A.
107. Doggett RS, Colby TV, Dorfman RF. Interfollicular Hodgkin's disease. Am J Surg Pathol. 1983;7:145–149.
108. Zarate-Osorno A, Medeiros LJ, Danon AD, et al. Hodgkin's disease with coexistent Castleman-like histologic features. A report of three cases. Arch Pathol Lab Med. 1994;118:270–274.
109. Rywlin AM, Rosen L, Cabello B. Coexistence of Castleman's disease and Kaposi's sarcoma. Report of a case and a speculation. Am J Dermatopathol. 1983;5:277–281.
110. Chen KT. Multicentric Castleman's disease and Kaposi's sarcoma. Am J Surg Pathol. 1984;8:287–293.
111. Kessler E, Beer R. Multicentric giant lymph node hyperplasia clinically simulating angioimmunoblastic lymphadenopathy. Associated Kaposi's sarcoma in two of three cases. Isr J Med Sci. 1983;19:230–234.
112. Dickson D, Ben-Ezra JM, Reed J, et al. Multicentric giant lymph node hyperplasia, Kaposi's sarcoma, and lymphoma. Arch Pathol Lab Med. 1985;109:1013–1018.
113. Lubin J, Rywlin AM. Lymphoma-like lymph node changes in Kaposi's sarcoma. Two additional cases. Arch Pathol. 1971;92:338–341.
114. Abe Y, Matsubara D, Gatanaga H, et al. Distinct expression of Kaposi's sarcoma-associated herpesvirus-encoded proteins in Kaposi's sarcoma and multicentric Castleman's disease. Pathol Int. 2006;56:617–624.
115. Naresh KN, Rice AJ, Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol. 2008;32:1006–1012.
116. Nishi J, Arimura K, Utsunomiya A, et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol. 1999;104:482–485.
117. Foss HD, Araujo I, Demel G, et al. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol. 1997;183:44–50.
This article has been cited 8 time(s).
Journal of CancerInfectious Diseases Are Analogous With Cancer. Hypothesis And ImplicationsJournal of Cancer
Human PathologyThe number and growth pattern of plasmacytoid dendritic cells vary in different types of reactive Lymph nodes: an immunohistochemical studyHuman Pathology
Scientific ReportsNovel genetically-humanized mouse model established to evaluate efficacy of therapeutic agents to human interleukin-6 receptorScientific Reports
Pathology & Oncology ResearchMulticentric Castleman's Disease: A Challenging DiagnosisPathology & Oncology Research
Survey of OphthalmologyOrbital Involvement in Castleman DiseaseSurvey of Ophthalmology
World Journal of GastroenterologyClinicopathological features and prognosis assessment of extranodal follicular dendritic cell sarcomaWorld Journal of Gastroenterology
GastroenterologyA Rare Submucosal Tumor of the Stomach Answer to the Clinical Challenges and Images in GI Question: Image 3: Mixed Variant Castleman's Disease of the StomachGastroenterology
Medical OncologyClinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patientsMedical Oncology
Castleman disease; IL-6; HHV-8-positive plasmablastic lymphoma; follicular dendritic cell neoplasm; Kaposi sarcoma
© 2009 Lippincott Williams & Wilkins, Inc.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Highlight selected keywords in the article text.
Data is temporarily unavailable. Please try again soon.
Readers Of this Article Also Read